Search Results

Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.

• Authors : Kuwata H; Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.; Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Gastric Emptying/Gastric Emptying/Gastric Emptying/*drug effects ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

• Source: Journal of diabetes investigation [J Diabetes Investig] 2021 Dec; Vol. 12 (12), pp. 2162-2171. Date of Electronic Publication: 2021 Jun 16.Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702

Record details

Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.

• Authors : Shiomi M; Department of Clinical Pharmacy, School of Pharmacy, Kitasato University, Tokyo, Japan.; Department of Pharmacy, Kitasato University Medical Center, Saitama, Japan.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Diabetic Retinopathy/Diabetic Retinopathy/Diabetic Retinopathy/*epidemiology ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

• Source: Journal of diabetes investigation [J Diabetes Investig] 2019 Mar; Vol. 10 (2), pp. 408-417. Date of Electronic Publication: 2018 Aug 22.Publisher: Asian Association for the Study of Diabetes and Blackwell Pub. Asia Country of Publication: Japan NLM ID: 101520702

Record details

Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs.

• Authors : Takeuchi M; Mie Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Mie, Japan.; Licensing & Business Development, R&D Strategy Center, Sanwa Kagaku Kenkyusho Co., Ltd., Tokyo, Japan.

Subjects: Delayed-Action Preparations/Delayed-Action Preparations/Delayed-Action Preparations/*pharmacokinetics ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists; Animals

• Source: Drug research [Drug Res (Stuttg)] 2019 Sep; Vol. 69 (9), pp. 479-486. Date of Electronic Publication: 2019 May 13.Publisher: Thieme Country of Publication: Germany NLM ID: 101602406 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2194-9387

Record details

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.

• Authors : Hasegawa Y; Diabetes Center (Internal Medicine III), Tokyo Women's Medical University School of Medicine, Tokyo, Japan; Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.

Subjects: Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

• Source: Journal of clinical lipidology [J Clin Lipidol] 2018 Jan - Feb; Vol. 12 (1), pp. 62-69.e1. Date of Electronic Publication: 2017 Nov 21.Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.

• Authors : Kaku K; Department of General Internal Medicine 1, Kawasaki Medical School, Okayama, Japan.; Yamada Y

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*administration & dosage

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 May; Vol. 20 (5), pp. 1202-1212. Date of Electronic Publication: 2018 Feb 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.

• Authors : Seino Y; Kansai Electric Power Medical Research Institute, Kobe, Japan.; Kansai Electric Power Hospital, Osaka, Japan.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/Dipeptidyl-Peptidase IV Inhibitors/Dipeptidyl-Peptidase IV Inhibitors/*adverse effects ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Feb; Vol. 20 (2), pp. 378-388. Date of Electronic Publication: 2017 Oct 05.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes.

• Authors : Yamada, Tomoko; Asahara, Shun-ichiro; Kimura-Koyanagi, Maki

• Source: Diabetology International. July, 2023, Vol. 14 Issue 3, p294, 4 p.

Record details

Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.

• Authors : Usui R; Center for Diabetes, Endocrinology, and Metabolism, Kansai Electric Power Hospital, 2-1-7 Fukushima-ku, Osaka, 553-0003, Japan.; Yabe D

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/Glucagon-Like Peptide-1 Receptor/*agonists ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

• Source: Journal of diabetes and its complications [J Diabetes Complications] 2015 Nov-Dec; Vol. 29 (8), pp. 1203-10. Date of Electronic Publication: 2015 Jul 21.Publisher: Elsevier Science Pub. Co Country of Publication: United States NLM ID: 9204583 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.

• Authors : Tanaka, Yuki; Iwaya, Chikayo; Kawanami, Takako

• Source: Diabetology International. July, 2022, Vol. 13 Issue 3, p480, 13 p.

Record details

Nippon Boehringer Ingelheim Co. Ltd. Reports Findings in Obesity (A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in ...)

• Source: Asia Business Newsweekly. 2023, pages. 100

Record details